Leukemia

Over the past decades, Brazil has become the world's leading soybean producer, as well as the leading consumer of pesticides. Despite concerns about potential public health consequences, little is known about the effects of pesticide…

Initial topline data from COVALENT-101 trial revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4Dose Level 4 exposure correlates with initial activity…

FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to…

Published in the Journal of Clinical Oncology, University of Minnesota Medical School researchers led a study that demonstrated the safety of using microbiota transplant therapy (MTT) in patients with acute myeloid leukemia (AML) -- a type…

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years after infusionSingle-cell analysis of…

Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen…

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of…

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH). The data from the NHS…

Dennis Thompson FRIDAY, June 16, 2023 (HealthDay News) -- Using gas stoves can increase indoor air levels of benzene, a chemical linked to higher risk of leukemia and other blood cell cancers,…

Elana Gotkine TUESDAY, June 13, 2023 (HealthDay News) -- Fixed-duration ibrutinib plus venetoclax is beneficial for patients with chronic lymphocytic leukemia, including those with high risk…